NATERA INC
NASDAQ: NTRA (Natera, Inc.)
Last update: 21 hours ago203.75
2.61 (1.30%)
| Previous Close | 201.14 |
| Open | 201.14 |
| Volume | 986,734 |
| Avg. Volume (3M) | 1,211,860 |
| Market Cap | 29,091,119,104 |
| Price / Sales | 12.18 |
| Price / Book | 17.00 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -10.36% |
| Operating Margin (TTM) | -15.78% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | 36.50% |
| Total Debt/Equity (MRQ) | 15.78% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | 153.12 M |
| Levered Free Cash Flow (TTM) | 120.93 M |
| Return on Assets (TTM) | -8.87% |
| Return on Equity (TTM) | -18.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Natera, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.90 |
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.24% |
| % Held by Institutions | 96.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 31 Dec 2025 | 3,914,366 |
| Duquesne Family Office Llc | 31 Dec 2025 | 2,511,357 |
| Castle Hook Partners Lp | 31 Dec 2025 | 2,167,869 |
| Fred Alger Management, Llc | 31 Dec 2025 | 1,822,508 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 260.00 (Evercore ISI Group, 27.61%) | Buy |
| Median | 253.50 (24.42%) | |
| Low | 215.00 (Wells Fargo, 5.52%) | Hold |
| Average | 245.50 (20.49%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 207.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 03 Mar 2026 | 250.00 (22.70%) | Buy | 207.04 |
| Baird | 27 Feb 2026 | 257.00 (26.13%) | Buy | 208.04 |
| Evercore ISI Group | 27 Feb 2026 | 260.00 (27.61%) | Buy | 208.04 |
| Wells Fargo | 27 Feb 2026 | 215.00 (5.52%) | Hold | 208.04 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SHEENA JONATHAN | - | 208.40 | -1,500 | -312,600 |
| Aggregate Net Quantity | -1,500 | |||
| Aggregate Net Value ($) | -312,600 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 208.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SHEENA JONATHAN | Director | 17 Apr 2026 | Automatic sell (-) | 1,500 | 208.40 | 312,600 |
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes |
| 02 Feb 2026 | Announcement | Natera Submits Signatera™ CDx PMA to FDA |
| 28 Jan 2026 | Announcement | Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation |
| 26 Jan 2026 | Announcement | Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |